Advertisement

Endometrial Cancer Prevention

  • Paulina Cybulska
  • Mario M. LeitaoJrEmail author
Chapter
  • 364 Downloads

Abstract

Endometrial cancer is the most common malignancy of the female genital tract. Type and extent of disease at presentation and survival outcomes vary by race. The prevention of these cancers entails the prevention and treatment of associated precursor lesions. There are both modifiable and non-modifiable risks for endometrial cancer and their precursors, and preventive strategies should take this into consideration. This chapter is divided into sections on preventive strategies based on known and putative risk factors.

Keywords

Endometrial cancer Endometrial hyperplasia Endometrial carcinoma Lynch syndrome Cowden syndrome Risk factors Screening Prevention Metabolic syndrome 

References

  1. Aarnio M, Mecklin JP, Aaltonen LA et al (1995) Life-time risk of different cancers in hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64:430–433PubMedCrossRefPubMedCentralGoogle Scholar
  2. Adams TD, Stroup AM, Gress RE et al (2009) Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 17:796–802CrossRefGoogle Scholar
  3. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRefPubMedCentralGoogle Scholar
  4. Ali S, Fonseca V (2012) Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother 13:1797–1805PubMedCrossRefPubMedCentralGoogle Scholar
  5. Anderson KE, Anderson E, Mink PJ et al (2001) Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 10:611–616PubMedPubMedCentralGoogle Scholar
  6. Argenta P, Svendsen C, Elishaev E et al (2014) Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery. Gynecol Oncol 133:78–82PubMedCrossRefPubMedCentralGoogle Scholar
  7. Attner B, Landin-Olsson M, Lithman T et al (2012) Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control 23:769–777PubMedCrossRefPubMedCentralGoogle Scholar
  8. Baak JP, Mutter GL, Robboy S et al (2005) The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 103:2304–2312PubMedPubMedCentralCrossRefGoogle Scholar
  9. Bansal N, Yendluri V, Wenham RM (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16(1):8–13. https://doi.org/10.1177/107327480901600102PubMedCrossRefPubMedCentralGoogle Scholar
  10. Barakat RR, Gilewski TA, Almadrones L et al (2000) Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 18:3459–3463PubMedCrossRefPubMedCentralGoogle Scholar
  11. Beavis AL, Cheema S, Holschneider CH et al (2015) Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep 13:71–75PubMedPubMedCentralCrossRefGoogle Scholar
  12. Bjorge T, Stocks T, Lukanova A et al (2010) Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 171:892–902PubMedCrossRefPubMedCentralGoogle Scholar
  13. Black D, Bogomolniy F, Robson ME et al (2005) Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol Oncol 96:21–24PubMedCrossRefPubMedCentralGoogle Scholar
  14. Bonadona V, Bonaïti B, Olschwang S, et al; French Cancer Genetics Network (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304–2310Google Scholar
  15. Brasky TM, Potter JD, Kristal AR, Patterson RE, Peters U, Asgari MM, Thornquist MD, White E (2012) Nonsteroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes & Control 23(3):431–444CrossRefGoogle Scholar
  16. Brasky TM, Liu J, White E, Peters U, Potter JD, Walter RB, Baik CS, Lane DS, Manson JAE, Vitolins MZ, Allison MA, Tang JY, Wactawski-Wende J (2014) Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women’s Health Initiative. Int J Cancer 135(8):1869–1883.  https://doi.org/10.1002/ijc.28823CrossRefPubMedPubMedCentralGoogle Scholar
  17. Burn J, Gerdes A, Macrae F et al (2011) Long-term effect of aspirin on cancer risk in carries of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087PubMedPubMedCentralCrossRefGoogle Scholar
  18. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591.  https://doi.org/10.1038/nrc1408CrossRefPubMedGoogle Scholar
  19. Cantrell LA, Zhou C, Mendivil A et al (2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 116:92–98PubMedCrossRefPubMedCentralGoogle Scholar
  20. Catalano S, Giordano C, Rizza P et al (2009) Evidence that leptin through STAT and CREB signaling enhances Cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol 218:490–500PubMedCrossRefPubMedCentralGoogle Scholar
  21. Chen L, Yang KY, Little SE et al (2007) Gynecologic cancer prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer families. Obstet Gynecol 110:18–25PubMedCrossRefPubMedCentralGoogle Scholar
  22. Chin J, Konje JC, Hickey M (2009) Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev (4):CD007245.  https://doi.org/10.1002/14651858.CD007245.pub2
  23. Clark LH, Ko EM, Kernodle A et al (2016) Endometrial cancer survivors’ perceptions of provider obesity counseling and attempted behavior change: are we seizing the moment? Int J Gynecol Cancer 26:318–324PubMedCrossRefGoogle Scholar
  24. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedPubMedCentralCrossRefGoogle Scholar
  25. Cust AE, Kaaks R, Friedenreich C et al (2007) Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 14:755–767PubMedCrossRefGoogle Scholar
  26. Daniels MS (2012) Genetic testing by cancer site: uterus. Cancer J 18(4):338–342.  https://doi.org/10.1097/PPO.0b013e3182610cc2CrossRefPubMedGoogle Scholar
  27. Davies C, Pan H, Godwin J, et al (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 381(9869):805–816Google Scholar
  28. Dominick S, Hickey M, Chin J et al (2015) Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev (12):CD007245Google Scholar
  29. Dottino JA, Hasselblad V, Secord AA et al (2016) Levonorgestrel intrauterine device as an endometrial cancer prevention strategy in obese women: a cost-effectiveness analysis. Obstet Gynecol 128:747–753PubMedCrossRefGoogle Scholar
  30. Dove-Edwin I, Boks D, Goff S et al (2002) The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94:1708–1712PubMedCrossRefGoogle Scholar
  31. Felix AS, Yang HP, Bell DW et al (2017) Epidemiology of endometrial carcinoma: etiologic importance of hormonal and metabolic influences. Adv Exp Med Biol 943:3–46PubMedCrossRefGoogle Scholar
  32. Friedenreich CM, Biel RK, Lau DCW et al (2011) Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Epidemiol Biomarkers Prev 20:2384–2395CrossRefGoogle Scholar
  33. Garofalo C, Surmacz E (2006) Leptin and cancer. J Cell Physiol 207:12–22PubMedCrossRefGoogle Scholar
  34. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60(4):207–221.  https://doi.org/10.3322/caac.20078CrossRefPubMedPubMedCentralGoogle Scholar
  35. Guillen-Ponce C, Molina-Garrido M, Carrato A (2012) Follow-up recommendations and risk-reduction initiatives for Lynch syndrome. Exp Rev Anticancer 12:1359–1367CrossRefGoogle Scholar
  36. Gunderson CC, Dutta S, Fader AN et al (2014) Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecol Oncol 132:33–37PubMedCrossRefPubMedCentralGoogle Scholar
  37. van Hanegem, N., Breijer, M. C., Slockers, S. A., Zafarmand, M. H., Geomini, P., Catshoek, R., et al. (2017). Diagnostic workup for postmenopausal bleeding: a randomised controlled trial. BJOG, 124(2), 231–240. doi: https://doi.org/10.1111/1471-0528.14126CrossRefPubMedPubMedCentralGoogle Scholar
  38. Haoula Z, Salman M, Atiomo W (2012) Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 27(5):1327–1331.  https://doi.org/10.1093/humrep/des042CrossRefPubMedGoogle Scholar
  39. Hecht JL, Ince TA, Baak JPA et al (2005) Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 18:324–330PubMedPubMedCentralCrossRefGoogle Scholar
  40. Jones ME, van Leeuwen FE, Hoogendoorn WE et al (2012) Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 14:R91PubMedPubMedCentralCrossRefGoogle Scholar
  41. Kakuta Y, Nakaya N, Nagase S et al (2009) Case-control study of green tea consumption and the risk of endometrial endometrioid adenocarcinoma. Cancer Causes Control 20:617–624PubMedCrossRefPubMedCentralGoogle Scholar
  42. Kosary CL (2007) Cancer of the corpus uteri. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, editors. SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, patient and tumor characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD.Google Scholar
  43. Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia: a long-term study of “untreated” hyperplasia in 170 patients. Cancer 56:403–412PubMedCrossRefPubMedCentralGoogle Scholar
  44. Kwon JS, Lu KH (2008) Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women. Obstet Gynecol 112:56–63PubMedCrossRefPubMedCentralGoogle Scholar
  45. Lauby-Secretan B, Scoccianti C, Loomis D, et al; International Agency for Research on Cancer Handbook Working Group (2016) Body fatness and cancer—viewpoint of the IARC working group. N Engl J Med 375:794–798PubMedCrossRefPubMedCentralGoogle Scholar
  46. Leitao MM Jr, Kehoe S, Barakat RR et al (2008) Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 111:244–248PubMedCrossRefPubMedCentralGoogle Scholar
  47. Leitao MM Jr, Kehoe S, Barakat RR et al (2009) Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 113:105–108PubMedCrossRefPubMedCentralGoogle Scholar
  48. Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507–1517PubMedPubMedCentralCrossRefGoogle Scholar
  49. Linkov F, Maxwell GL, Felix AS et al (2012) Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction. Gynecol Oncol 125:114–119PubMedCrossRefPubMedCentralGoogle Scholar
  50. Linkov F, Elishaev E, Gloyeske N et al (2014) Bariatric surgery-induced weight loss changes immune markers in the endometrium of morbidly obese women. Surg Obes Relat Dis 10:921–926PubMedCrossRefPubMedCentralGoogle Scholar
  51. Lu KH, Dinh M, Kohlmann W et al (2005) Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105:569–574PubMedCrossRefPubMedCentralGoogle Scholar
  52. Lu KH, Schorge JO, Rodabaugh KJ et al (2007) Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol 25:5158–5164PubMedCrossRefPubMedCentralGoogle Scholar
  53. Luo J, Chlebowski RT, Hendryx M et al (2017) Intentional weight loss and endometrial cancer risk. J Clin Oncol 35:1189–1193PubMedPubMedCentralCrossRefGoogle Scholar
  54. MacDonald PC, Edman CD, Hemsell DL et al (1978) Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 130:448–455PubMedCrossRefPubMedCentralGoogle Scholar
  55. Mahdi H, Mester JL, Nizialek EA et al (2015) Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: an international, multicenter, prospective study. Cancer 121:688–696PubMedCrossRefPubMedCentralGoogle Scholar
  56. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25(2):544–551. https://doi.org/10.1093/humrep/dep399PubMedCrossRefPubMedCentralGoogle Scholar
  57. McCawley GM, Ferriss JS, Geffel D et al (2009) Cancer in obese women: potential protective impact of bariatric surgery. J Am Coll Surg 208:1093–1098PubMedCrossRefPubMedCentralGoogle Scholar
  58. Modesitt SC, Hallowell PT, Slack-Davis JK et al (2015) Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Gynecol Oncol 138:238–245PubMedCrossRefPubMedCentralGoogle Scholar
  59. Moon HS, Chamberland JP, Aronis K et al (2011) Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther 10:2234–2243PubMedPubMedCentralCrossRefGoogle Scholar
  60. Mueck AO, Seeger H, Rabe T (2010) Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer 17:R263–R271PubMedCrossRefPubMedCentralGoogle Scholar
  61. Murali R, Soslow RA, Weigelt B (2014) Classification of endometrial carcinoma: more than two types. Lancet Oncol 15:e268–e278PubMedCrossRefPubMedCentralGoogle Scholar
  62. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, Barker A, Perry JRB, Attia J, Dunning AM, Easton DF, Holliday E, Lotta LA, O’Mara T, McEvoy M, Pharoah PDP, Scott RJ, Spurdle AB, Langenberg C, Wareham NJ, Scott RA (2015) Evidence of a causal association between insulinemia and endometrial cancer: a mendelian randomization analysis. J Natl Cancer Inst 107(9):djv178–djv178.  https://doi.org/10.1093/jnci/djv178CrossRefPubMedPubMedCentralGoogle Scholar
  63. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 7:e33411PubMedPubMedCentralCrossRefGoogle Scholar
  64. Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity in the United States, 2009–2010. NCHS data brief, no. 82. National Center for Health Statistics, Hyattsville, MDGoogle Scholar
  65. Oliver KE, Enewold LR, Zhu K, Conrads TP, Rose GS, Maxwell GL, Farley JH (2011) Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecol Oncol 123(1):76–81.  https://doi.org/10.1016/j.ygyno.2011.06.027CrossRefPubMedGoogle Scholar
  66. Ollberding NJ, Lim U, Wilkens LR et al (2012) Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the Multiethnic Cohort Study. J Natl Cancer Inst 104:67–76PubMedCrossRefPubMedCentralGoogle Scholar
  67. Ostlund MP, Lu AY, Lagergen J (2010) Risk of obesity-related cancer after obesity surgery in a population-based cohort study. Ann Surg 252:972–976PubMedCrossRefPubMedCentralGoogle Scholar
  68. Parker WH, Broder MS, Chang E et al (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstet Gynecol 113:1027–1037PubMedPubMedCentralCrossRefGoogle Scholar
  69. Patel AV, Feigelson HS, Talbot JT et al (2008) The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer 123:1877–1882PubMedCrossRefPubMedCentralGoogle Scholar
  70. Pilarski R (2009) Cowden syndrome: a critical review of the clinical literature. J Genet Couns 18:13–27PubMedCrossRefPubMedCentralGoogle Scholar
  71. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12(3):159–169.  https://doi.org/10.1038/nrc3215CrossRefPubMedGoogle Scholar
  72. Reeves KW, Carter GC, Rodabough RJ et al (2011) Obesity in relation to endometrial cancer risk and disease characteristics in the Women’s Health Initiative. Gynecol Oncol 2011:376–382CrossRefGoogle Scholar
  73. Renehan AG, Roberts DL, Dive C (2008) Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 114:71–83PubMedCrossRefPubMedCentralGoogle Scholar
  74. Renkonen-Sinisalo L, Butzow R, Leminen A et al (2007) Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 120:821–824PubMedCrossRefPubMedCentralGoogle Scholar
  75. Rijcken FEM, Mourits MJE, Kleibeuker JH et al (2003) Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 91:74–80PubMedCrossRefPubMedCentralGoogle Scholar
  76. Rosato V, Zucchetto A, Bosetti C et al (2011) Metabolic syndrome and endometrial cancer risk. Ann Oncol 22:884–889PubMedCrossRefPubMedCentralGoogle Scholar
  77. Schmeler KM, Lynch HT, Chen L et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch Syndrome. N Engl J Med 354:261–269PubMedPubMedCentralCrossRefGoogle Scholar
  78. Schouten LJ, Goldbohm RA, van den Brandt PA (2004) Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst 96:1635–1638PubMedCrossRefPubMedCentralGoogle Scholar
  79. Schuler KM, Rambally BS, DiFurio MJ et al (2015) Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 4:161–173PubMedCrossRefPubMedCentralGoogle Scholar
  80. Seth D, Garmo H, Wigertz A et al (2012) Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study. Int J Mol Epidemiol Genet 3:122–133PubMedPubMedCentralGoogle Scholar
  81. Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67:7–30CrossRefGoogle Scholar
  82. Simpson ER, Clyne C, Rubin G et al (2002) Aromatase—a brief overview. Annu Rev Physiol 64:93–127PubMedCrossRefPubMedCentralGoogle Scholar
  83. Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, Massey C, Ferguson SE (2014) Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol 133(2):229–233PubMedCrossRefPubMedCentralGoogle Scholar
  84. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos A-K, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Carlsson LMS (2009) Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 10(7):653–662PubMedCrossRefGoogle Scholar
  85. Soler M, Chatenoud L, Negri E et al (1999) Hypertension and hormone-related neoplasms in women. Hypertension 34:320–325PubMedCrossRefPubMedCentralGoogle Scholar
  86. Stadler ZK, Robson ME (2015) Inherited predisposition to endometrial cancer: moving beyond Lynch syndrome. Cancer 121(5):644–647. https://doi.org/10.1002/cncr.29107PubMedCrossRefPubMedCentralGoogle Scholar
  87. Stevens RJ, Ali R, Bankhead CR et al (2012a) Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomized clinical trials. Diabetologia 55:2593–2603PubMedCrossRefPubMedCentralGoogle Scholar
  88. Stevens VL, Jacobs EJ, Sun J et al (2012b) Weight cycling and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 21:747–752PubMedCrossRefPubMedCentralGoogle Scholar
  89. Takahashi A, Kimura F, Yamanaka A et al (2014) Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int 14:53PubMedPubMedCentralCrossRefGoogle Scholar
  90. Tan M, Mester JL, Ngeow J et al (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400–407PubMedPubMedCentralCrossRefGoogle Scholar
  91. The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73PubMedCrossRefPubMedCentralGoogle Scholar
  92. Tingthanatikul Y, Choktanasiri W, Rochanawutanon M, Weerakeit S (2006) Prevalence and clinical predictors of endometrial hyperplasia in anovulatory women presenting with amenorrhea. Gynecol Endocrinol 22(2):101–105.  https://doi.org/10.1080/09513590600585997CrossRefPubMedGoogle Scholar
  93. Todoric J, Antonucci L, Karin M (2016) Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila) 9:895–905CrossRefGoogle Scholar
  94. Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108PubMedPubMedCentralCrossRefGoogle Scholar
  95. Torres ML, Weaver AL, Kumar S et al (2012) Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 120:998–1004PubMedPubMedCentralGoogle Scholar
  96. Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME, Brinton LA (2015) Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev 24(1):261–267.  https://doi.org/10.1158/1055-9965.EPI-14-0923CrossRefGoogle Scholar
  97. Trimble CL, Kauderer J, Zaino R et al (2006) Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106:812–819PubMedCrossRefPubMedCentralGoogle Scholar
  98. Tsilidis KK, Kasimis JC, Lopez DS et al (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350:g7607PubMedCrossRefPubMedCentralGoogle Scholar
  99. Upala S, Sanguankeo A (2015) Bariatric surgery and risk of postoperative endometrial cancer: a systematic review and meta-analysis. Surg Obes Relat Dis 11:949–955PubMedCrossRefPubMedCentralGoogle Scholar
  100. Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353–362PubMedPubMedCentralCrossRefGoogle Scholar
  101. Verdoodt F, Friis S, Dehlendorff C et al (2016) Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: a systematic review and meta-analysis of observational studies. Gynecol Oncol 140:352–358PubMedCrossRefPubMedCentralGoogle Scholar
  102. Villavicencio A, Aguilar G, Arguello G et al (2010) The effect of overweight and obesity on proliferation and activation of AMT and ERK in human endometria. Gynecol Oncol 117:96–102PubMedCrossRefPubMedCentralGoogle Scholar
  103. Wallace AE, Gibson DA, Saunders PT, Jabbour HN (2010) Inflammatory events in endometrial adenocarcinoma. J Endocrinol 206:141–157PubMedCrossRefGoogle Scholar
  104. Wan YL, Holland C (2011) The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric 14:622–632PubMedCrossRefGoogle Scholar
  105. Ward KK, Roncancio AM, Shah NR et al (2014) Bariatric surgery decreases the risk of uterine malignancy. Gynecol Oncol 133:63–66PubMedCrossRefGoogle Scholar
  106. Weiderpass E, Persson I, Adami HO et al (2000) Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer. Cancer Causes Control 11:185–192PubMedCrossRefGoogle Scholar
  107. Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 19:61–109CrossRefGoogle Scholar
  108. Wright JD, Fiorelli J, Schiff PB et al (2009) Racial disparities for uterine corpus tumors. Cancer 115:1276–1285PubMedCrossRefGoogle Scholar
  109. Yu W, Cline M, Maxwell LG et al (2010) Dietary vitamin D exposure prevents obesity-induced increase in endometrial cacner in Pten+/- mice. Cancer Prev Res 3:1246–1258CrossRefGoogle Scholar
  110. Zaino RJ, Kauderer J, Trimble CL et al (2006) Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106:804–811PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Gynecology Service, Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations